Cryoprecipitate
Cryoprecipitate
Cryoprecipitate (pronounced: kryo-pre-sip-i-tate), also known as Cryo, is a type of blood product made from plasma. It is rich in certain clotting factors and is used to treat or prevent bleeding in some conditions, such as hemophilia and von Willebrand disease.
Etymology
The term "Cryoprecipitate" is derived from the Greek words "kryos" meaning cold, and "precipitate" which refers to the process of forming a solid from a solution. It was first used in the 1960s when it was discovered that cooling and then slowly rewarming plasma caused a precipitate to form that was rich in clotting factors.
Usage
Cryoprecipitate is used in the treatment of conditions that involve a deficiency of clotting factors, such as hemophilia A, von Willebrand disease, and Factor XIII deficiency. It is also used in cases of massive transfusion where there is significant dilution of clotting factors.
Preparation
Cryoprecipitate is prepared by freezing fresh frozen plasma and then slowly thawing it at 1 to 6 degrees Celsius. The precipitate that forms is then separated from the remaining plasma and can be pooled from multiple donors to create a single unit of Cryoprecipitate.
Components
Cryoprecipitate contains a concentrated amount of certain clotting factors, including Factor VIII, von Willebrand factor, Factor XIII, fibrinogen, and platelet microparticles.
Risks
As with any blood product, there are risks associated with the use of Cryoprecipitate. These include the risk of transfusion reaction, transfusion transmitted infection, and volume overload.
See Also
External links
- Medical encyclopedia article on Cryoprecipitate
- Wikipedia's article - Cryoprecipitate
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski